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ASPEK KLINIKAL DAN TOKSIKOLOGI BERKAITAN KERACUNAN 
PARASETAMOL, DAN PREDIKTOR - PREDIKTOR KESUDAHANNYA 
 
ABSTRAK 
 
Parasetamol merupakan satu sumber keracunan yang lumrah; dan pengenalpastian awal 
pesakit-pesakit yang mengalami keracunan yang lebih teruk adalah kunci kepada 
memperbaiki kesudahan. Banyak aspek toksisiti parasetamol dan rawatannya masih 
kurang difahami. Untuk meningkatkan pengetahuan mengenai keracunan parasetamol, 
kajian 5 tahun berasaskan-hospital ini telah dilaksanakan dengan objektif-objektif utama 
seperti berikut: (1) untuk menentukan corak keracunan parasetamol dalam kalangan 
pesakit yang dimasukkan ke Hospital Pulau Pinang (HPP); dan (2) untuk mengenalpasti 
indikator-indikator prognosis buruk semasa presentasi awal di hospital bagi 
meningkatkan penjagaan klinikal dan menentukan sasaran-sasaran intervensi untuk 
pencegahan, pengesanan awal, diagnosis dan rawatan. Ini adalah satu kajian pemerhatian 
kohort retrospektif mengenai kemasukan ke hospital bagi kes keracunan parasetamol akut 
antara 1 Januari 2004 dan 31 Disember 2008. 
 
Secara keseluruhannya, 305 orang pesakit telah memenuhi kriteria penyertaan. 
Manifestasi gastrousus (GI)  lazimnya berlaku dalam kalangan pesakit yang dilaporkan 
menelan  ≥ 8 grams parasetamol, di mana masa latensi adalah melebihi 8 jam; dan kedua-
dua faktor ini telah dikenalpasti sebagai prediktor yang bebas dan kukuh untuk kehadiran 
manifestasi GI, terutamanya loya/muntah. Kehadiran gejala-gejala GI merupakan satu 
penanda penting bagi kesudahan yang buruk dan peningkatan  jangka masa pesakit 
tinggal di hospital. Selain itu, hipokalemia mempunyai kaitan yang tinggi dengan 
keracunan parasetamol. Ciri-ciri klinikal yang spesifik semasa presentasi awal di hospital, 
seperti muntah, penyakit psikiatrik, dan dos parasetamol yang dilaporkan ditelan, boleh 
digunakan untuk mengenalpasti pesakit yang mempunyai risiko tinggi untuk mendapat 
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hipokalemia. Yang penting, jangka masa lama  tinggal di hospital berkurang dengan 
ketara apabila terapi IV-NAC diberikan dalam tempoh 8 jam selepas pengambilan 
parasetamol (p = 0.006). Tindakbalas advers drug (ADR) terhadap terapi IV-NAC biasa 
berlaku dalam kalangan pesakit keracunan parasetamol, tetapi kebanyakannya adalah kes 
ringan dan mudah dirawat: tiada kematian dilaporkan. Kepekatan parasetamol yang 
rendah dalam serum mempunyai kaitan yang ketara dengan gejala kulit kemerah-merahan 
atau flushing (p < 0.001), ruam (p < 0.001) dan gatal-gatal (p < 0.001). Tambahan pula, 
infusi NAC yang lambat diberikan mempunyai kaitan yang ketara dengan tindakbalas 
anafilaktoid kutaneus, apabila dibandingkan dengan pesakit yang tidak mengalami ADR 
jenis ini (p < 0.001).  Akhir sekali, dalam kebanyakan keracunan diri yang disengajakan 
(DSP), pesakit mengalami pelbagi tekanan hidup dan penyakit psikiatri, yang boleh 
dikaitkan dengan niat membunuh diri yang berbeza-beza tingkatnya. Masalah alkohol 
merupakan satu-satunya kategori tekanan hidup yang ketara berbeza antara jantina. 
Tambahan pula, dalam kajian semasa, pesakit DSP lelaki mengambil parasetamol dalam 
dos yang lebih banyak, dan oleh itu, pesakit lelaki mungkin terdedah kepada risiko yang 
lebih tinggi. 
 
Kesimpulannya, kajian ini adalah yang pertama seumpamanya untuk menilai hubungan di 
antara ciri-ciri klinikal pesakit keracunan parasetamol semasa dimasukkan ke hospital, 
dan semasa berada di hospital. Pengetahuan mengenai ciri klinikal dan kaitannya dengan 
kesudahan mungkin menyumbang kepada pengurangan kadar komplikasi dengan 
meningkatkan penjagaan klinikal dan menentukan sasaran-sasaran untuk intervensi. Hasil 
kajian ini akan membolehkan pakar perubatan dan pakar toksikologi klinikal 
mengenalpasti pesakit yang mempunyai risiko tinggi untuk mendapat toksisiti 
parasetamol dan kebarangkalian berlakunya hepatotoksisiti kemudiannya supaya rawatan 
dapat dimulakan. 
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CLINICAL AND TOXICOLOGICAL ASPECTS ASSOCIATED WITH 
PARACETAMOL POISONING, AND PREDICTORS OF ITS OUTCOMES 
 
ABSTRACT  
Paracetamol is a common source of poisoning, and early identification of patients with 
more severe poisoning is the key to improving outcomes. Many aspects of paracetamol 
toxicity and treatment remain poorly understood. To improve knowledge about 
paracetamol poisoning, the current 5-year, hospital-based study was carried out with the 
following primary objectives (1) to determine the pattern of paracetamol poisoning 
among patients who were admitted to Hospital Pulau Pinang (HPP); and (2) to identify 
indicators of poor prognosis at first hospital presentation for improving clinical care and 
determining intervention targets for prevention, early detection, diagnosis and treatment. 
This is an observational retrospective cohort study of hospital admissions for acute 
paracetamol poisoning between 1 January 2004 and 31 December 2008.  
 
Overall, 305 patients met the inclusion criteria. Gastrointestinal (GI) manifestations were 
common in patients who reported ingestion of ≥ 8 g of paracetamol, and whose latency 
was longer than 8 hours; and both of these factors were identified as strong independent 
predictors of the presence of GI manifestations, especially nausea/vomiting. The presence 
of GI symptoms was a significant marker of poor outcomes and increased hospital stays. 
Additionally, hypokalaemia is highly associated with paracetamol poisoning. Specific 
clinical characteristics upon first presentation to the hospital, such as vomiting, 
psychiatric illness, and reported paracetamol dose ingested, can be used to identify 
patients at increased risk for hypokalaemia. Importantly, long hospital stays were 
significantly less frequent when IV-NAC therapy was administered within 8 hours of 
paracetamol ingestion (p = 0.006). Adverse Drug Reactions (ADRs) to IV-NAC therapy 
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are common in paracetamol poisoning patients, but are mostly minor and easily managed; 
no fatalities were observed. Low serum paracetamol concentrations are significantly 
associated with flushing (p < 0.001), rash (p < 0.001) and pruritus (p < 0.001). 
Furthermore, delayed NAC infusions were significantly associated with cutaneous 
anaphylactoid reactions, when compared to patients without this type of ADR (p < 
0.001). Finally, most paracetamol deliberate self-poisoning (DSP) patients suffer from 
different life stressors and psychiatric illnesses, which may be associated with varying 
degrees of suicidal intentions. Alcohol problems were the only life stressor category 
which was significantly different between genders. Moreover, in the current study, male 
DSP patients ingested higher amounts of paracetamol, and therefore male patients might 
be at a higher risk. 
 
In conclusion, this is the first study of its kind to evaluate the relationship between the 
clinical characteristics of paracetamol poisoned patients upon hospital admission, and 
during hospitalization. Knowledge of clinical characteristic and their relation to outcome 
might contribute to reduced complication rates by improving clinical care and 
determining targets for intervention. The results from this study will allow physicians or 
clinical toxicologists to identify patients who are at increased risk of paracetamol toxicity 
and the probability of subsequent hepatotoxicity so as to initiate treatment.  
 
 
 
1 
 
 
 
 
 
 
CHAPTER 1 
 
 GENERAL INTRODUCTION AND LITERATURE REVIEW OF 
PARACETAMOL  
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1.1 INTRODUCTION 
 
The terms acetaminophen (used in the United States, Canada, other Latin American 
countries, Hong Kong, Iran, and Colombia) and paracetamol (used elsewhere) 
(Bradley, 1996) both derive from chemical names for the compound: para-
acetylaminophenol and para-acetylaminophenol. In some situations, it is simply 
abbreviated as APAP, for N-acetyl-para-aminophenol (Hoffman et al., 2007). 
 
Paracetamol was synthesised by Morse in Germany in 1878, and subsequently 
produced by numerous methods. Paracetamol was introduced into clinical practice by 
Von Mering in 1893 (Haas, 1983). Shortly after, it was replaced in Germany by 
phenacetin, since phenacetin was assumed to be safer than paracetamol. Paracetamol 
was found in the urine of patients who had taken phenacetin and was recognised as a 
metabolite of another analogue of phenacetin, acetanilide (Bateman and Dear, 2010). A 
key development in the history of paracetamol occurred in 1948, when Brodie and 
Axelrod, evaluating the effects of phenacetin, identified paracetamol as the major active 
hepatic metabolite of phenacetin (Brodie and Axelrod, 1948). By this time phenacetin 
was documented to have kidney toxicity, and the use of paracetamol as an analgesic 
was promoted in its place (Brodie and Axelrod, 1949). 
 
Paracetamol (Tylenol®) was first marketed in the United States of America (USA) in 
1955 by McNeil Laboratories, as an analgesic and antipyretic for children. In 1956, the 
United Kingdom (UK) Company Frederick Stearns & Co. marketed paracetamol as 
Panadol®, in a 500 mg tablet, and in 1958 they produced a paracetamol containing 
children’s elixir as a prescribed pain killer and antipyretic (Bateman and Dear, 2010). It 
is now the best-selling analgesic in the USA (Woodcock et al., 2011). 
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Although the British medical establishment was initially cautious, in 1963 paracetamol 
was added to the British National Formulary (List, 1963), and as such became more 
commonly used as an analgesic, especially when phenacetin was banned from the 
market in the 1970s (Bateman and Dear, 2010).  
 
Paracetamol has since proven to be a remarkably safe drug at appropriate dosages, 
making it the antipyretic-analgesic of choice for various conditions (Hoffman et al., 
2007).  
Paracetamol (Panadol®) was introduced in Malaysia in 1957, and by 1962, Sterling 
Drug Malaysia began business in Malaysia, marketing Panadol® to hospitals initially, 
thereby gaining acceptance from the medical community. By the 1970s, Panadol® had 
gained enormous popularity, and could be found almost everywhere, from pharmacies 
to supermarkets and clinics. In fact, Panadol® has become the foremost over-the-
counter pain reliever in Malaysia (GlaxoSmithKline, 2007a; GlaxoSmithKline, 2007b). 
Paracetamol has since proven to be a remarkably safe drug at appropriate dosages, 
making it the antipyretic-analgesic of choice for various conditions (Hoffman et al., 
2007). Paracetamol in Malaysia is available alone, in numerous single-agent dose 
formulations and delivery systems, and in a wide variety of combinations with 
antihistamines, other analgesics, decongestants, expectorants, opioids, and sedatives. 
Common brand names for paracetamol include Panadol®, Arfen®, Avadol ®, Axcel 
Paracetamol®, Hoemal®, Panadol Actifast®, Panadol Extend®, Panadol Soluble®, 
Parafizz®, Paratamol®, Poro®, Rapidol®, Remedol®, Tempol®, and Uphamol® 
(MIMS Malaysia, 2011). 
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The main topics under investigation in this thesis are: i) early prediction of paracetamol 
poisoning/overdose outcomes; ii) evaluation of management patterns for acute 
paracetamol poisoned patients and hospital stay; iii) the adverse reactions caused by 
intravenous infusion of N-acetylcysteine (NAC); and iv) risk factors and life stressors 
contributing to paracetamol poisoning. This introductory chapter includes four separate 
parts. In part 1, pharmacology and toxicology of paracetamol are discussed. In part 2, 
outcomes and prognostic indicators following paracetamol poisoning are reviewed. In 
part 3, the management of paracetamol poisoning is reviewed. Finally, in part 4, NAC 
treatment of paracetamol poisoning and its associated adverse reactions are discussed.  
 
1.2 PHARMACOLOGY AND TOXICOLOGY OF PARACETAMOL 
1.2.1 Pharmacology 
Paracetamol is an antipyretic and analgesic with weak peripheral anti-inflammatory 
properties. Antipyretic activity is reported at serum paracetamol concentrations 
between 4-18 mcg/mL, and analgesic activity at 10-20 mcg/mL (Wilson, 1985; Stocker 
and Montgomery, 2001; Hoffman et al., 2007). 
 
In spite of its popularity, the mechanism(s) by which paracetamol achieves its 
antipyretic and analgesic effects is still being debated (Anderson, 2008; Toussaint et al., 
2010). Antipyretic activity is mediated by central nervous system (CNS) inhibition of 
prostaglandin E2 (PGE2) synthesis, via either inhibition of membrane-associated PGE 
synthase or direct inhibition of cyclooxygenase (COX)-2 (Aronoff and Neilson, 2001; 
Graham and Scott, 2005). PGE synthase inhibition may be a result of local reductions 
of glutathione (GSH) concentrations, initiated by metabolic processing of paracetamol 
to reactive metabolites via the hepatic cytochrome P450 enzyme system (Graham and 
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Scott, 2005; Toussaint et al., 2010). Furthermore, binding and inhibition of COX-3 by 
paracetamol may have an antipyretic effect (Botting, 2000; Chandrasekharan et al., 
2002; Botting and Ayoub, 2005); although the idea that paracetamol acts directly 
through COX-3 has been rejected (Kis et al., 2005; Williams et al., 2011). 
 
The analgesic effect of paracetamol is also mediated by central inhibition of PG 
synthase and COX-2, and probably via indirect modulation of serotonergic pathways 
(Graham and Scott, 2005; Anderson, 2008). Additional effects may be related to 
indirect stimulation of endogenous opioid pathways (Raffa et al., 2000; Raffa et al., 
2004) .  
 
Some studies have also suggested that paracetamol may have mild anti-inflammatory 
effects (Graham and Scott, 2005; Aronoff et al., 2006; Hinz et al., 2008; Flood, 2010). 
A German study on healthy volunteers orally administered 1000 mg paracetamol found 
substantial and selective inhibition of COX-2 (>80%), similar to the effects reported for 
non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (Hinz 
et al., 2008). This study also demonstrated that COX-1 inhibition, as measured by 
thromboxane B2 (TXB2) synthesis, was minor (56%), and not sufficient for the 
inhibition of platelet function (Hinz et al., 2008). These data support an anti-
inflammatory action by paracetamol, and explain why it has a better overall 
gastrointestinal (GI) safety profile than NSAIDs (Bannwarth, 2004; Gonzalez-Perez 
and Rodriguez, 2006; Hinz et al., 2008). 
 
6 
 
1.2.2 Pharmacokinetics 
Following oral ingestion, therapeutic doses of paracetamol are rapidly absorbed, and 
peak blood levels are reached within approximately 1 hour (Prescott, 1981), while 
liquid paracetamol levels peak in 30 minutes (Ameer et al., 1983). Extended-release 
paracetamol has a time to peak of 1-2 hours, but is almost completely absorbed by 4 
hours (Tan and Graudins, 2006). Even when taken in toxic doses, absorption of 
paracetamol is approximately complete within 4 hours, with no additional rise in blood 
levels after this time (Prescott et al., 1971). However, in an Australian study, Roberts 
and Buckley (2008) reported a case of acute poisoning from extended-release 
paracetamol presented 14.5 hours post-ingestion. The paracetamol absorption phase and 
elimination half-life appeared prolonged, with peak blood concentrations occurring at 
20 hours post-ingestion (Roberts and Buckley, 2008). Time to peak can be delayed by 
anticholinergic agents or coingestion of opioids (Halcomb et al., 2005) and food 
(Divoll et al., 1982). 
 
The oral bioavailability of paracetamol is 60-98% following administration of 
therapeutic dose, ranging between 8-32 mcg/mL (Hoffman et al., 2007). Paracetamol 
has a total protein binding of 10-30%, which does not change with toxic doses 
(Milligan et al., 1994). Paracetamol crosses both the blood brain barrier (van der Marel 
et al., 2003; Kumpulainen et al., 2007) and placenta (Levy et al., 1975; Wilkes et al., 
2005). 
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After ingestion of therapeutic doses of paracetamol in adults, first-pass metabolism 
eliminates 25% of the therapeutic dose (Hoffman et al., 2007). Once absorbed, 
approximately 90% of the ingested paracetamol is metabolised to phenolic glucuronide 
(40-67%) and sulphate (20-46%) in the liver, by uridine diphosphate (UDP)-
glucuronosyltransferases and sulfotransferases, forming inactive metabolites which are 
subsequently excreted in the urine (Schenker et al., 2001; Hoffman et al., 2007; Larson, 
2007; Chun et al., 2009; Klein-Schwartz and Doyon, 2011); (Figure 1.1). Although a 
small portion of un-metabolised paracetamol (<5%) and other minor metabolites 
reaches the urine, these are not considered to be clinically significant (Prescott, 1996b; 
Schenker et al., 2001; Rumack, 2002; Larson, 2007). The residual fraction, which 
usually ranges between 5-15%, is metabolised by the hepatic cytochrome P450 enzyme 
system (cytochrome 2E1: CYP2E1, and, to a lesser extent, cytochrome 1A2: CYP1A2, 
cytochrome 2A6: CYP2A6, and cytochrome 3A4: CYP3A4 isoenzymes); (Manyike et 
al., 2000; Hazai et al., 2002; Hoffman et al., 2007), resulting in the formation of N-
acetyl-p-benzoquinoneimine (NAPQI), a highly toxic metabolite. GSH quickly 
combines with this intermediate metabolite, and the resulting complex is converted into 
nontoxic cysteine or mercaptate conjugates which are eliminated in the urine (Mitchell 
et al., 1974; Prescott, 1996b). The elimination half-life of paracetamol is approximately 
2-3 hours after a nontoxic dose, but may become extended in patients who develop 
hepatotoxicity (Prescott et al., 1971).  
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Figure 1.1. Important routes of paracetamol metabolism in humans, and 
mechanisms of N-acetylcysteine (NAC) hepatoprotection; Adapted from Hoffman et 
al., 2007; Reproduced with permission of the McGraw-Hill Companies. 
 
APAP: N-acetyl-p-aminophenol=paracetamol; NADP=nicotinamide adenine 
dinucleotide phosphate; CYP=Cytochrome; UDP=uridine diphosphate; NAC1: 
augments sulfation; NAC2 is a glutathione (GSH) precursor; NAC3 is a GSH substitute; 
and NAC4 improves multiorgan function during hepatic failure and possibly limits the 
extent of hepatocyte injury; NAPQI = N-acetyl-p-benzoquinoneimine. 
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1.2.3 Toxicology 
In general, paracetamol is a safe drug when taken at therapeutic dosages. Even after 
poisoning, the majority of paracetamol absorption takes place within 2 hours. Peak 
plasma concentrations are normally reached within 4 hours, while later peaks are rarely 
predictable in paraceta (Tighe and Walter, 1994; Prescott, 1996b). The lowest 
oral/ingested dose of paracetamol which is generally considered to be able to cause 
toxicity is 7.5 g in adults and 150 mg/kg in children (Hoffman et al., 2007; Saccomano 
and Deluca, 2008). In addition, it is believed that toxicity in general occurs at doses 
above 150 mg/kg (Hoffman et al., 2007). 
 
1.2.3.1 Mechanism of toxicity 
Following a clinically significant overdose of paracetamol, hepatic GSH becomes 
depleted and the formation of reactive intermediate metabolites (i.e. NAPQI) exceeds 
detoxification rates; saturation of the normal nontoxic routes (i.e. sulfation) of 
metabolism then becomes significant as toxicity progresses enabling NAPQI to bind 
covalently to hepatocellular proteins, leading liver cell damage and eventually resulting 
in cell death and liver failure (Prescott, 1980). The quantity of NAPQI produced is 
increased out of proportion to the paracetamol dose, because maximal rates of sulfation 
are exceeded (Davis et al., 1976). Although glucuronidation was initially believed to be 
saturable, it is probable only saturated in severely poisoned patients. In addition to an 
increase in the formation of toxic metabolites, general elimination is prolonged as 
normal metabolic systems become saturated (Hoffman et al., 2007); (see Figure 1.1). 
 
The mechanisms of liver injury are not yet fully understood but recent reports had 
suggested that NAPQI could directly interact with macromolecules in the liver cell 
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causing lipid peroxidation, protein dysfunction, damage of deoxyribonucleic acid 
(DNA), oxidative stress and peroxynitrite formation in the mitochondria (Letelier et al., 
2011; Loguidice and Boelsterli, 2011; Mitchell et al., 2011; Ramachandran et al., 
2011b). A more recent study by Ramachandran et al. (2011a) showed that the oxidative 
stress and peroxynitrite formation are responsible for mitochondrial DNA damage and 
opening of the mitochondrial membrane permeability transition pore, which generates 
the collapse of the mitochondrial membrane potential and stops ATP formation. 
Furthermore, another recent study reported that the consequential of mitochondrial 
swelling lead to the burst of the outer membrane with the release of intermembrane 
proteins and subsequent nuclear DNA fragmentation and necrotic cell death (Jaeschke 
et al., 2011). Dysfunction of mitochondria possibly will thereby result in disrupting 
energy production, interrupting ionic gradients and intracellular calcium stores resulting 
in cell death and liver damage (Holt and Ju, 2006; Larson, 2007; Ferner et al., 2011; 
Mitchell et al., 2011). A more recent study by Li et al. (2011) suggested that initial 
changes of hepatocyte injury included basal membrane disruption and loss of 
mitochondrial membrane potential leading to irreversible paracetamol-induced 
hepatocyte injury.  
 
1.2.3.2 Factors affecting toxicity  
The toxicity of paracetamol is amplified by several factors that cause GSH depletion, 
such as increased production of the toxic metabolite NAPQI, or reduced antioxidative 
capacity of the liver (Thomas, 1993). Furthermore, low protein diets caused GSH 
depletion, and thus enhanced paracetamol toxicity (McLean and Day, 1975). A number 
of drugs, such as carbamazepine, phenytoin, phenobarbital, phenytoin, primidone, and 
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rifampicin induce cytochrome P450 enzymes, and thus increase subsequent formation 
of the toxic metabolite NAPQI (Miners et al., 1984). 
 
The effects of ethanol ingestion on paracetamol toxicity are complex, and the role of 
ethanol in acute poisoning remains controversial (Hoffman et al., 2007). Acute ethanol 
ingestion presumably reduces toxic metabolic activation, because ethanol competitively 
inhibits CYP2E1, preventing metabolism of paracetamol to NAPQI. Therefore, co-
administration of ethanol with paracetamol may be somewhat hepatoprotective 
(Schmidt et al., 2002a; Waring et al., 2008b). In contrast, chronic excessive alcohol 
ingestion can induce CYP2E1, consequently increasing the potential toxicity of 
paracetamol (Schmidt et al., 2002a; Gomez-Moreno et al., 2008; Ansari, 2010; 
Megwas and Izuawuba, 2010). 
 
Vitamin E reduction also increases paracetamol toxicity, possibly by impairing the 
hepatic response to oxidative stress (Sener et al., 2003). On the other hand, paracetamol 
toxicity is reduced by GSH production induced by hepatic enzyme inhibitors, such as 
cimetidine (Prescott, 1996b; Sajedianfard et al., 2009). Paracetamol toxicity is also 
reduced by antioxidants (Oz et al., 2004). Reducing agents, such as ascorbic acid, 
enhance the conversion of NAPQI back to paracetamol and inhibit the covalent binding 
of paracetamol metabolites to liver microsomal protein (Mitra et al., 1991; Abraham, 
2005). Also, the toxicity of paracetamol is increased in patients with a negative nitrogen 
balance, such as those with cancer (Barker et al., 1977). 
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1.2.3.3 Clinical features of poisoning 
1.2.3.3.1 Diagnosis  
Early detection and treatment of patients with paracetamol poisoning is essential for 
preventing morbidity and mortality. However, this recognition is complicated by the 
lack of predictive clinical findings early in the course of paracetamol poisoning, and 
clinicians should not be reassured by a lack of clinical symptoms shortly after 
paracetamol ingestion. In fact, the first symptoms of paracetamol poisoning may be 
related to hepatic injury, and may develop many hours after ingestion, when antidotal 
therapy will have diminished efficacy.  
 
1.2.3.3.2 Early signs 
The first 24 hours are considered to be the first phase of paracetamol poisoning. Early 
clinical symptoms of paracetamol poisoning are usually non-specific, and include 
nausea and vomiting, malaise, pallor, and diaphoresis; while laboratory indices of liver 
function are typically normal (Hoffman et al., 2007). In very rare cases of massive 
overdose, decreased consciousness and metabolic acidosis may also occur during the 
first phase; although still without any signs or symptoms of hepatotoxicity (Roth et al., 
1999; Wiegand et al., 2010). Hepatic tenderness may first appear after about 12 hours 
and may persist for 18-72 hours (Prescott, 1983). However, these clinical findings 
should never be assumed to be due to paracetamol poisoning alone without a thorough 
assessment of other probable causes. 
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1.2.3.3.3 Hepatic toxicity 
In the second phase of paracetamol poisoning, the patient begins to develop clinical and 
laboratory evidence of hepatotoxicity. Although healthcare practitioners are usually 
taught that paracetamol-induced liver dysfunction takes place only after a latency of 24 
to 48 hours (Rowden et al., 2006); several studies have demonstrated that liver enzymes 
often become elevated during the first 24 hours (Singer et al., 1995; James et al., 2002; 
Green et al., 2010). 
 
Signs and symptoms during the second phase vary with the severity of liver injury, but 
are often similar to those of other causes of hepatocellular injury, such as hepatitis A. 
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT)  levels 
are the most sensitive, readily available marker for identification or prediction of the 
onset of hepatotoxicity, and AST/ALT abnormalities always precede evidence of 
definite liver dysfunction, such as prolonged prothrombin time (PT), elevated bilirubin 
concentrations, metabolic acidosis and hypoglycemia (Hoffman et al., 2007; Hinson et 
al., 2010). Although uncommon, elevated AST/ALT concentrations may be detectable 
as early as 8-12 hours after paracetamol ingestion (Singer et al., 1995; Rowden et al., 
2005; Green et al., 2010). A more recent studies reported asymptomatic ALT elevations 
in research subjects who were administered therapeutic doses (4 g/day or less) of 
paracetamol for more than 4 days (Heard, 2011; Sabate et al., 2011). Based on these 
studies, the authors recommended that toxicologists should consider therapeutic 
paracetamol use as a cause of ALT elevations (Heard, 2011; Sabate et al., 2011). While 
the clinical course of these elevations was not completely defined, available evidence 
suggests that, even in high risk groups, ALT elevations are not accompanied by 
14 
 
evidence of hepatic dysfunction, and are resolved if treatment is discontinued (Heard, 
2011).  
 
Following the second phase of paracetamol poisoning, patients enter a third phase, 
which is defined as the time of maximal hepatotoxicity, and most frequently occurs 
between 3 and 4 days after paracetamol ingestion. The most common clinical 
manifestations of this phase include fulminant hepatic failure (FHF) (Chun et al., 
2009). The clinical characteristics of FHF are progressive jaundice with hepatic 
encephalopathy, associated with markedly increased patient drowsiness and confusion; 
in addition, there may be impairment of blood clotting, causing spontaneous bruising 
and bleeding from needle sites, as well as flapping tremor and hypoglycemia. Cerebral 
oedema may also develop, resulting in headaches, a reduced level of consciousness and 
cardiac dysrhythmias (Prescott, 1996b).  
 
Fatalities from FHF commonly occur between 3 and 5 days after acute paracetamol 
poisoning, resulting from multiple organ failure, either alone or in combination with 
other complications, including: acute respiratory distress syndrome, haemorrhaging, 
cerebral oedema and sepsis (Bjornsson et al., 2005; Hoffman et al., 2007). Patients who 
survive this period (third phase) enter the fourth phase, which is defined as the recovery 
phase. Hepatic regeneration leads to full recovery in survivors. Although the rate of 
recovery varies, in most cases, laboratory test results are within the normal range by 5-7 
days after an acute paracetamol poisoning (McGregor et al., 2003; Grypioti et al., 2005; 
Grypioti et al., 2007; Hinson et al., 2010). However, full recovery may require 
significantly more time in severely poisoned patients, and histological abnormalities 
may persist for months (McGregor et al., 2003; Hoffman et al., 2007).  
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1.2.3.3.4 Renal failure 
Renal failure is less frequent than liver failure following paracetamol poisoning, and 
has been reported in less than 2% of all patients  (Prescott, 1983). However, the 
occurrence rate of renal failure is greater in more severely poisoned patients, and is 
observed in more than 50% of patients with hepatic failure, and in approximately 25% 
of patients with significant hepatotoxicity (Prescott, 1983). Less commonly, mild renal 
insufficiency occurs without elevations in aminotransferase levels, or as an isolated 
manifestation of paracetamol toxicity (Prescott et al., 1982; Kher and Makker, 1987; 
Boutis and Shannon, 2001).  
 
Renal failure is sometimes preceded by renal tenderness and back pain, accompanied 
by haematuria and proteinuria (Thomas, 1993). Renal failure is associated with 
elevations in plasma creatinine levels, beginning on day 2 and usually peaking between 
days 3 and 6 (Prescott, 1996b; Pakravan et al., 2009; Waring et al., 2010; O' Riordan et 
al., 2011), although progressive elevations of creatinine have been reported up to day 
16 (Davenport and Finn, 1988). In cases of paracetamol-induced FHF, the incidence of 
acute renal failure is nearly equal to that of patients with hepatic failure from other 
causes (Wilkinson et al., 1977).  
 
Although renal failure is a known complication of paracetamol toxicity, the causal 
mechanisms are poorly understood (Mazer and Perrone, 2008; Pakravan et al., 2009). 
Toxic metabolites of paracetamol are produced by local metabolism in the kidney, and 
may lead to acute tubular necrosis, mainly in conditions associated with GSH depletion 
(Mitchell et al., 1977). Even in the absence of acute renal failure, paracetamol 
poisoning is associated with short-term (<24 h) dose-dependent changes in electrolyte 
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transport, suggesting a specific renal effect of paracetamol poisoning, perhaps via 
cyclooxygenase inhibition mediated changes to renal tubular function (Pakravan et al., 
2007). Risk factors, such as dehydration at presentation, chronic excessive paracetamol 
poisoning,  concomitant ingestion of nephrotoxic substances, GSH depletion in the 
kidney, and pre-existing liver and renal insufficiency, may all increase the risk of renal 
injury following paracetamol poisoning (von Mach et al., 2005).  
 
Whereas GSH depletion is considered to play an important role in predisposing 
paracetamol poisoned patients to hepatotoxicity, there is a lack of data supporting a 
similar mechanism in renal failure (Waring et al., 2010). Other mechanisms of renal 
failure have been suggested, including lipid peroxidation and oxidative stress, through 
which paracetamol induces tubular epithelial degeneration and cortical interstitial 
congestion (Isik et al., 2006). In addition, COX inhibition has been proposed to be 
responsible for renal tubular injury in the presence of very high paracetamol 
concentrations, which might be present following poisoning (Waring et al., 2008a; 
Waring et al., 2010). 
 
1.2.3.3.5 Other features  
Hypoglycemia may occur between 12 and 72 hr after paracetamol poisoning, due to 
impairment of hepatic gluconeogenesis (Zabrodski and Schnurr, 1984); while metabolic 
acidosis with reduced bicarbonate levels may also be an early feature (Zabrodski and 
Schnurr, 1984; Zein et al., 2010). Metabolic acidosis occurs in approximately half of 
paracetamol poisoned patients within the first 15 hours, and is caused by inhibition of 
lactic acid uptake and metabolism by the liver, and subsequently, by worsening hepatic 
function and impaired hepatic clearance of lactic acid (Gray et al., 1987; Makin and 
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Williams, 1997; Bourdeaux and Bewley, 2007; Chun et al., 2009; Shah et al., 2011). 
Hypophosphatemia is commonly observed in conjunction with paracetamol-induced 
hepatotoxicity, and depends on the severity of liver damage, since it is believed to be 
caused by pronounced phosphate uptake by the regenerating liver (Schmidt and 
Dalhoff, 2002). 
 
Clinically noticeable cardiac disturbances are very uncommon following paracetamol 
poisoning. Electrocardiogram (ECG) abnormalities and myocardial injury, which were 
first noted in early case reports (Jones and Prescott, 1997), are most often observed in 
patients with FHF, but never as an isolated problem (Lip and Vale, 1996); however, in 
some cases these effects may be caused by hypokalemia, which is common in the early 
stages of paracetamol poisoning (Heaps and Gormley, 2010). Recently, Contractor et 
al. (2011) reported a case with paracetamol poisoning in which the patient developed 
widespread ST-elevation. An emergency echocardiogram was recorded, revealing 
global hypokinesia, consistent with a moderate degree of systolic left ventricular 
impairment. The authors propose that paracetamol poisoning-mediated myocardial 
injury occurs via a mechanism similar to that responsible for hepatic damage. 
Specifically, paracetamol is partially converted to NAPQI, a toxic metabolite which is 
in normally activated by glutathione reduction; NAPQI then acts as a direct toxin on the 
myocardium. Furthermore, paracetamol itself has been shown to covalently bind 
proteins in both cardiac and liver tissues, causing protein structural and functional 
changes, and potentially precipitating cytokine release and tissue damage (Contractor et 
al., 2011). 
 
18 
 
Hyperamylasemia and pancreatitis have been reported in paracetamol poisoning, either 
alone or in combination with ethanol abuse (Schmidt and Dalhoff, 2004; Hoffman et 
al., 2007). Acute pancreatitis, which is characterised by acute abdominal pain and 
paralytic ileus, has been reported in paracetamol poisoning, generally after an interval 
of 1-5 days (Schmidt and Dalhoff, 2004; Igarashi et al., 2009). 
 
1.2.3.4 Toxicoepidemiology 
1.2.3.4.1 Global toxicoepidemiology 
Paracetamol is considered to be one of the most common causes of poisoning 
worldwide; and is the leading subject of inquiries to poison centres in the UK and USA 
(Hawton et al., 2009; Bronstein et al., 2010).  
 
Vale in 2003 documented that up to 40% of all hospital admissions for self-poisoning 
in the UK involved paracetamol (Vale, 2003). Since the mid-1970s, there had been an 
increase in the number of paracetamol poisoning, such that paracetamol in 2009 had 
become the substance most commonly used in deliberate self-poisoning (DSP) in the 
UK (Hawton et al., 2009).  In Oxford, UK, the percentage of paracetamol poisoned 
cases increased from 14.3% in 1976 to 42% in 1990; while in 1993, 47.8% of all 
poisoned cases involved either paracetamol or paracetamol-containing drugs (Hawton 
and Fagg, 1992; Hawton et al., 1996). In fact, paracetamol accounts for half of all 
poisoning admissions to UK hospitals annually, and is involved in an estimated 150 
deaths per year (Hawkins et al., 2007).  
 
Nourjah et al. (2006) estimated the number of paracetamol-associated poisoning in the 
USA. The authors found that paracetamol-associated poisoning cases account for 
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approximately 56,000 emergency room visits and 26,000 hospitalisations yearly. In 
addition, analysis of national mortality files revealed that 458 deaths occurred each year 
from paracetamol-associated poisoning; 100 of which are unintentional. The poison 
surveillance database reported a near-doubling of the number of fatal cases associated 
with paracetamol: from 98 in 1997 to 173 in 2001 (Nourjah et al., 2006). A more recent 
USA study, conducted by Manthripragada et al, (2011), suggested that both intentional 
and unintentional paracetamol poisoning remain a significant public health concern. 
Furthermore, another recent USA study conducted by Li and Martin (2011), found that 
children less than 5 years of age, adolescents and young adults account for an 
overwhelming majority of the emergency department visits attributed to paracetamol 
poisoning.  
 
1.2.3.4.2 Malaysian toxicoepidemiology  
Paracetamol poisoning has also become an emerging problem in Malaysia. 
Fathelrahman et al. (2005) determined the pattern of acute drug and chemical poisoning 
at Penang General Hospital (PGH), in the northern region of Malaysia. In this 
retrospective study, the authors found that paracetamol was the main causative agent 
(44.7%) among cases associated with drugs, and was implicated in 33.47% of all 
poisoning incidents (Fathelrahman et al., 2005).  
 
Another retrospective review of medical records was conducted to determine the 
pattern of drug and chemical poisoning cases admitted to the Hospital Universiti Sains 
Malaysia, in the state of Kelantan (Ab Rahman, 2002). In this study, cases of poisoning 
with medicinal substances were more common than those with traditional medicines. 
Medicinal substances included therapeutic drugs such as aspirin and paracetamol 
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(21.9%), as well as salicylate-containing products (6.7%); hypnotics and sedatives 
(5.3%); and external preparations (2.3%). The author suggested that paracetamol 
poisoning did not seem to significantly contribute to the overall pattern of poisoning, in 
contrast with reports that cases of paracetamol poisoning are increasing elsewhere (Ab 
Rahman, 2002). 
 
Another cross-sectional survey study conducted in Malaysia used a questionnaire to 
determine the top 10 toxic agents most commonly reported by accident and emergency 
departments (AED) as responsible for cases of poisoning during the preceding year at 
their hospital. Among the responding hospitals, paracetamol poisoning ranked first, and 
was reported by 86.5% of the hospitals (Al-Sohaim et al., 2011).  
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1.3 DIAGNOSTIC TESTING 
1.3.1 Assessing the risk of paracetamol toxicity 
A risk assessment, in which the clinician attempts to determine the most effective 
clinical course and predict potential complications based on a patient’s presentation, 
should occur as soon as possible during the management of all poisoning patients. The 
key factors to consider in paracetamol poisoning are the history of the ingested dose 
and the concentration (early predictors), as well as clinical and laboratory features 
suggesting hepatic damage (late predictors), and any patient history suggesting an 
increased risk for toxicity (Daly et al., 2008).  
 
Fatalities from paracetamol poisoning are frequent but avoidable, with appropriate 
diagnosis and treatment. However, at the same time, the overwhelming majority of 
paracetamol exposures result in no toxicity. Thus an appropriate approach must be 
taken to avoid costs associated with unnecessary overtreatment, while eliminating 
patient risk. To balance these apparently disparate goals, clinicians must be aware of 
the basis for and sensitivity of current toxicity screening methods (Rowden et al., 2006; 
Hoffman et al., 2007). 
 
To evaluate and assess patient risk for subsequent toxicity, clinicians often only have 
unreliable ingestion histories, and measurements of paracetamol levels. However, as 
described above, the quantity and rate of NAPQI formation, the hepatic GSH supply, 
the equilibrium of NAPQI formation (CYP2E1 activity), and the capacity for non-toxic 
metabolism, are all major determinants of toxicity (Rumack and Matthew, 1975). 
Therefore, the best approach for determining patient risk following paracetamol 
poisoning would involve assessment of each of these factors. Until recently, none of 
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these toxicity measures was accessible to clinicians (Schilling et al., 2010). In addition, 
although the profile of urinary paracetamol metabolites may reveal increased NAPQI 
formation (Davis et al., 1976), there is no indication or suggestion that NAPQI 
measurements are of any predictive value in any given case. Furthermore, plasma GSH 
concentration can also be measured, but have a doubtful relationship with hepatic GSH 
availability (Smith et al., 1996).  
 
1.3.2 Risk determination after acute poisoning 
Acute paracetamol poisoning is generally considered to be a single ingestion, although 
in reality, many patients poisoning incrementally over a brief period of time. For 
purposes of this discussion, an acute overdose/ poisoning is defined as one in which 
complete ingestion occurs within a single 4-hour period. In fact, ingestion of 7.5 g of 
paracetamol in an adult, or 150 mg/kg in a child, is widely considered to be the lowest 
acute dose capable of causing toxicity (Prescott, 1983). While these principles have 
been widely applied as sensitive markers, they are not based on human data and are 
quite conservative. Although there is significant variation in patient susceptibility to 
paracetamol (Prescott, 1996a), animal data suggest that a single dose of at least 15 g is 
necessary to cause significant GSH depletion in a human adult (Mitchell et al., 1974).  
 
Hoffman et al. (2007) suggest that the ingested dose of paracetamol reported by adults 
may be considered to be less contentious than that reported for children, because 
variable histories, massive ingestions, and factors that might influence toxicity occur 
mainly in adults, allowing continued use of 7.5 g as a screening quantity to avoid 
missing serious toxicity. In any case, the dose history should be used in the estimation 
of risk only if there is reliable confirmation or evidence of validity. For example, dose 
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estimates may be useful in assessment of risk in many cases of unintentional or 
therapeutic paracetamol ingestion. When the history suggests possible risk, however, 
the reported dose is inadequate evidence on which to base treatment decisions; risk 
should then be estimated by determining serum paracetamol concentrations (Hoffman 
et al., 2007). 
 
Interpretation of serum paracetamol concentrations following acute exposure is based 
on an adaptation of the Rumack-Matthew nomogram (Rumack and Matthew, 1975). A 
drug nomogram developed in 1975, called the Rumack-Matthew nomogram, estimates 
toxicity risk based on the serum paracetamol concentration at a given number of hours 
after ingestion. Serum paracetamol levels at or above a line connecting 200 mcg/mL at 
4 hours post-ingestion and 30 mcg/mL at 15 hours post-ingestion were found to 
consistently predict hepatotoxicity (Rumack and Matthew, 1975); (Figure 1.2). 
 
When the nomogram was introduced in the United States, the US Food and Drug 
Administration (FDA) required an alteration of the original nomogram as part of the 
NAC protocol, resulting in a 25% reduction of the NAC treatment threshold. A line 
connecting 150 mcg/mL at 4 hours and 4.7 mcg/mL at 24 hours, was defined as the 
‘possible toxicity’ treatment line, to allow for possible errors in plasma assays and 
ingestion times (Rumack et al., 1981); (Figure 1.2). After an acute ingestion, serum 
paracetamol levels should be measured 4 hours post-ingestion, or at any time up to 24 
hours post-ingestion, and plotted on the nomogram. Patients with paracetamol levels 
above the ‘possible toxicity’ line should be treated with NAC (Rumack, 2002; Rowden 
et al., 2005). Paracetamol concentrations measured within the first 4 hours of ingestion 
may underestimate the amount of drug in the system, because paracetamol may still be 
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in the process of being absorbed from the GI tract. Therefore, serum concentration 
measurements within the first 4 hours post-ingestion are not recommended (Dart et al., 
2006).  
 
 
Figure 1.2. Plasma acetaminophen (paracetamol) concentrations versus time post-
paracetamol ingestion: Reproduced with permission from pediatrics, vol. 55, page 
873, Copyright © 1975 by the American Academy of Pediatrics (AAP).*The Rumack-
Matthew nomogram for determining the risk of paracetamol-induced hepatoxicity 
following a single acute ingestion. Levels above the treatment line on the nomogram 
indicate the need for N-acetylcysteine (NAC) therapy. 
 
The basic goals of risk assessment should be to determine serum paracetamol 
concentrations at the earliest point at which they will be significant. Measurement of 
serum paracetamol concentrations 4 hours post-ingestion, or as soon as possible 
thereafter, is used to confirm risk of toxicity, and thus the need to initiate NAC. 
Although it is optimal to start NAC therapy as soon as possible after confirmation of 
risk, most patients will have good outcomes if therapy is started before 8 hours post-
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ingestion (Smilkstein et al., 1988). Although this recommendation is not a permit to 
delay initiation of NAC treatment until 8 hours post-ingestion, it allows clinicians some 
flexibility to wait for serum paracetamol concentration laboratory results before 
deciding to start therapy; especially for patients whose history of paracetamol ingestion 
suggests that serum paracetamol concentrations will fall under the treatment line. 
Factors that confuse diagnostic decision making after acute paracetamol poisoning 
include: circumstances that prevent serum paracetamol concentration measurements 
prior to 8 hours post-ingestion; unable to determine the time of ingestion; patient 
brought to the hospital more than 24 hours post-ingestion; and newer formulations of 
paracetamol (Rumack, 2002; Rumack, 2004) . 
 
Only if serum paracetamol concentration determination results cannot be obtained 
within 8 hours of poisoning should history alone be used to decide to initiate NAC 
therapy. In such cases, serum paracetamol concentrations should still be determined as 
soon as possible. The result, when it does become accessible, should be interpreted in 
relation to the treatment line on the paracetamol nomogram, and NAC therapy should 
be either continued or ceased based on this result. In rare circumstances where no 
determination of serum paracetamol concentrations can ever be obtained, evidence of 
possible risk by history alone is adequate to initiate and complete a course of NAC 
therapy (Rumack, 2002; Hoffman et al., 2007). 
 
